CORT
NASDAQ · Pharmaceuticals
Corcept Therapeutics Inc
$71.63
-7.59 (-9.58%)
Financial Highlights (FY 2026)
Revenue
668.41M
Net Income
87.48M
Gross Margin
98.3%
Profit Margin
13.1%
Rev Growth
+23.7%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 98.3% | 98.3% | 41.7% | 41.7% |
| Operating Margin | 5.9% | 5.3% | 27.9% | 25.4% |
| Profit Margin | 13.1% | 12.4% | 22.8% | 19.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 668.41M | 540.17M | 785.70M | 815.78M |
| Gross Profit | 657.04M | 530.99M | 328.03M | 340.58M |
| Operating Income | 39.30M | 28.59M | 219.32M | 207.21M |
| Net Income | 87.48M | 63.63M | 178.89M | 159.66M |
| Gross Margin | 98.3% | 98.3% | 41.7% | 41.7% |
| Operating Margin | 5.9% | 5.3% | 27.9% | 25.4% |
| Profit Margin | 13.1% | 12.4% | 22.8% | 19.6% |
| Rev Growth | +23.7% | +23.7% | +17.7% | +19.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 406.47M | 449.40M |
| Total Equity | — | — | 2.76B | 2.61B |
| D/E Ratio | — | — | 0.15 | 0.17 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 40.33M | 30.96M | 255.84M | 269.33M |
| Free Cash Flow | — | — | 116.31M | 99.81M |